Try our beta test site

Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by University of Pavia.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
University of Pavia
ClinicalTrials.gov Identifier:
NCT01038895
First received: December 23, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

December 23, 2009
December 23, 2009
November 2009
March 2010   (Final data collection date for primary outcome measure)
Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria. [ Time Frame: 3 months ]
Same as current
No Changes Posted
  • Average of 24 hours by ABPM, systolic and diastolic blood pressure [ Time Frame: 3 months ]
  • Average daytime, systolic and diastolic blood pressure [ Time Frame: 3 months ]
  • Average night, systolic and diastolic blood pressure [ Time Frame: 3 months ]
Same as current
Not Provided
Not Provided
 
Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria
Not Provided

The main objective of this study is to assess the extent and trend in time of antiproteinuric effect as well as that antihypertensive effect of aliskiren 300 mg / d versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria. The investigators will also evaluate:

  1. Average of 24 hours, as determined by ABPM, systolic and diastolic blood pressure checks at various visits
  2. Average daytime, as determined by ABPM, systolic and diastolic blood pressure checks at various visits 3. Average night, as determined by ABPM, systolic and diastolic blood pressure checks at various visits
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hypertension
  • Type 2 Diabetes
  • Drug: Ramipril
    tablet; 10 mg; od; 3 months
  • Drug: Experimental
    tablet; 300 mg; od; 3 months
  • Active Comparator: Ramipril
    10 mg/daily
    Intervention: Drug: Ramipril
  • Experimental: Aliskiren
    300 mg/ daily
    Intervention: Drug: Experimental
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
120
June 2011
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • blood pressure > 130/80 <180/105 mmHg at the end of the wash−out

    • type 2 diabetes mellitus well controlled by medication and / or compliance with diet (HbA1c <7%)
    • microalbuminuria in the upper range of normal (> 200 <300 mg/24 h)

Exclusion Criteria:

  • Pregnancy, lactation or women of childbearing age
  • Sitting diastolic blood pressure e 105 mmHg or systolic pressure e 180 at the end of the period of wash−out
  • History of hypertensive encephalopathy or cerebrovascular accident within 6 months
  • Secondary hypertension
  • Heart Failure
  • Myocardial infarction within 6 months
  • Angina pectoris, clinically significant valvular disease or arrhythmia
  • Alteration indices of liver function or renal
  • Known hypersensitivity to ACE inhibitors
  • All other physiological or pathological condition in the opinion of the physician may affect the evaluation of the parameters under study
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01038895
UNIPV002DIM2009
2009-016481-83 ( Registry Identifier: 2009-016481-83 )
No
Not Provided
Not Provided
Not Provided
University of Pavia
University of Pavia
Not Provided
Study Director: Roberto Fogari, MD University of Pavia
University of Pavia
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP